newsfilter
← Latest News
GlobeNewswire·

MiNK Therapeutics Reports Q1 2025 Results and Highlights Clinical & Strategic Progress

Clinical data builds with CR in testicular cancer, enrollment in Phase 2 gastric trial, and new data in PD-1–resistant tumors Near-term capital transactions poised to bolster liquidity NEW YORK, May 15, 2025